MONTPELLIER, France--(BUSINESS WIRE)--Sensorion, a biotech company specializing in the treatment of inner ear diseases, today announced that it has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential.
The French Tech is a French initiative created in 2013 which incorporates metropolitan hubs known for their innovative start-ups. It aims to identify 200 to 300 small and medium enterprises (SME) throughout France with substantial development potential, in order to help them accelerate their growth and support their international expansion by providing them with a service offer and access to numerous networks of experts.
French Tech Pass certification provides promising companies preferential access to the financial, networking, and coaching services provided by Bpifrance, Business France, DGE (Direction Générale des Entreprises, or Directorate-General for Enterprise), Coface and Inpi and to the French Tech Pass regional partners and French Tech community networks.
For its third wave of certifications, the Montpellier Méditerranée Métropole French Tech mission panel chose, for the first time, start-ups from outside the digital sector. Sensorion has been granted this certification in recognition of its dynamic development, scientific and clinical breakthroughs, and technological potential to provide solutions to the particularly debilitating pathologies of the inner ear, a market estimated to be worth over $10 billion worldwide1.
Laurent Nguyen, CEO of Sensorion, comments: “We are delighted to have received French Tech Pass certification. This recognition further validates the company’s unique expertise and demonstrates the belief in our ability to become a leading SME in the field of inner ear pathologies which can lead to highly-debilitating vertigo, hearing loss and tinnitus. This certification will enable us to gain access to an ecosystem of private and public entities committed to the values of innovation and have the ability to support our development.”
1 Source: Alcimed, Sensorion
ISIN code: FR0012596468